Our main priority at Adaptimmune is to improve the outcomes of patients who are suffering from cancer via immunotherapy.
Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.
We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.
Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.
Adaptimmune Reports Q1 Financial Results
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020